Currently, more than 100,000 people in the United States are waiting for an organ transplant. Kidney patients account for most of the demand, and more than 90,000 people want to obtain donor organs. Statistics show that 17 people die every day while waiting for new organs. At the same time, a new patient is added to the waiting list every ten minutes.
biology3D printingSuch modern technologies may one day eliminate the need for treatments such as dialysis, and companies like Organovo used to be3D printingPioneer in the kidney field.Now, Israel’s CollPlant Biotechnologies and United Therapeutics are further strengthening their cooperation to perform biological treatment on the kidneys.3D printing, The ultimate goal is to transplant.
3D printing
Lung stent” alt=”
3D printing
The lung support” width=”245″ height=”300″ />
3D printingLung Stent ©2020 United Therapeutics Corp.
CollPlant CEO Yehiel Tal explained: “The shortage of organs is an unmet need for global health. In the past two years, through cooperation with United Therapeutics, we have made significant progress in this key organ manufacturing program.”
CollPlant is fully committed to “regenerative medicine and aesthetic medicine” related to tissue regeneration and human organ formation.For biological3D printing, The CollPlant team relies on its rhCollagen-based bio-ink. As a complement to The CollPlant technology, United Therapeutics is committed to developing products to improve the treatment of patients with chronic and life-threatening health problems.
The two companies have been collaborating since 2018 and have a great enthusiasm for CollPlant technology. They use tobacco plants to create plants that express collagen, which can lead to the production of multiple human organs.
“Our collagen-expressing plants have flourished in Texas, where we have experienced three growing seasons,” said Dr. Martine Rothblatt, Chairman and CEO of United Therapeutics.
The two companies initially cooperated for use in lung transplantation3D printing. Then, their collaboration expanded to include a payment of $3 million to CollPlant for the license of its collagen and bio-ink products. The initial agreement includes 5 million US dollars, of which “milestone payment is up to 15 million US dollars”, depending on the development details.
Yehiel Tal, CEO of CollPlantSaid: “United Therapeutics is exploring the emerging field of organ manufacturing, and we are honored to participate in this effort through this partnership. This choice proves another important verification of our rhCollagen platform technology, which can be used as a regenerative The best components of medicine. We are still committed to medical aesthetics and tissues and organs3D bioprintingExplore new innovative applications in the field. ”
(Editor in charge: admin)
0 Comments for “Two Israeli companies collaborate to expand lung transplantation to 3D printed kidneys”